Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Acquires Evalve
Abbott has acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320m, plus a $90m payment if certain regulatory
Abbott has acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320m, plus a $90m payment if certain regulatory
Gilead Sciences (Gilead), in collaboration with GlaxoSmithKline (GSK) has announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a
Novavax has made a poster presentation on the “Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults” at the 47th annual
Quintiles has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas around the globe. Quintiles is expected to assume
Prasco Laboratories has entered into agreements with Winthrop US, a business of sanofi-aventis US. As per the agreemnts, it is expected to provide sales support and distribution services
Boston Scientific has received CE mark for its Promus Element Everolimus-Eluting Coronary Stent System (PEEECSS), the company’s third-generation drug-eluting stent (DES) technology. Boston Scientific will begin marketing the
EnzymeRx has launched its first clinical study for Uricase-PEG20. The company said that subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single
Schering-Plough has reported that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a phase III study of adult subjects in
PRA International opened a new office facility in Seoul, South Korea. To accommodate rapid growth and further broaden PRA’s ability to deliver clinical service excellence, the company has
Valeant Pharmaceuticals (Valeant) has reported a total revenue of $220.3m for the third quarter of 2009, an increase of 31% compared to $168.4m in the third quarter of